UCB's Global Corporate Website

This section is intended for media and financial analysts

Key Financials

FY2022 (31 December 2022), if not indicated otherwise

For detailed information, download the annual reports in our download center.




Based on UCB’s current assessment of the COVID-19 pandemic, UCB remains confident in the fundamental underlying demand for its products and its prospects for long-term growth. UCB will continue to closely follow evolving COVID-19 pandemic diligently to assess potential near- and mid-term challenges.

The figures of the guidance 2023 and 2025 as mentioned below were calculated on the same basis as the actual figures for 2022.

2023 Revenue

€ 5.15 - 5.35 billion

based on expected launch contributions, the full annualized negative impact from the loss of exclusivity for VIMPAT® in the U.S. and Europe, and continued solid contribution from the existing product portfolio

2023 adj. EBITDA 

22.5% - 23.5%

reflecting investments in the upcoming launches and the late-stage development pipeline, continued strong cost discipline and annualized inflation impact

2023 Core EPS

€ 3.40 - € 3.80

based on an average of 190 million shares outstanding

2025 Revenue

at least € 6 billion

2025 adj. EBITDA

Low- to mid-thirties

2025 Improved ESG

rating performance


Product Sales

Strong underlying net sales growth thanks to a resilient product portfolio & new launches.

NAYZILAM® only available in the U.S., EVENITY® sales outside of Europe reported by Amgen and Astellas

VIMPAT® peak sales guidance

≥ € 1.5 billion by 2022

achieved in 2021

CIMZIA® peak sales guidance

≥ € 2 billion by 2024

achieved in 2022

BRIVIACT® peak sales guidance

≥ € 600 million in 2026


Cash Flows

The evolution of cash flow generated by bio-pharmaceutical activities is affected by the following:

  • Cash flow from operating activities amounted to € 1 119 million, all related to continuing operations, compared to € 1 553 million in 2021. The cash inflow stems from underlying net profitability, lower outstanding receivables, offset with lower payables and working capital stemming from the Zogenix acquisition.
  • Cash flow from investing activities showed an outflow of € 1 580 million from continuing operations, compared to € 487 million in 2021 and includes the acquisition of Zogenix (€ 1 212 million, net of cash), tangible (€ 252 million) and intangible (€ 119 million) capital expenditures.
  • Cash flow from financing activities had an inflow of € 70 million, which includes mainly the proceeds of the US$ 800 million bullet term loan facility offset by the dividend paid to UCB shareholders (€ -247 million) and the repayment of the convertible senior notes issued by Zogenix (€ -262 million).


Debt Financing

Net financial debt of € 2 000 million as per end December 2022, an increase of € 1 140 million compared to € 860 million as of end December 2021. The increase is related to the acquisition of Zogenix in March 2022, the 2021 dividend, offset with the underlying net profitability. The net debt to adjusted EBITDA ratio for 2022 is 1.6.

UCB has established a Euro Medium Term Note (EMTN) Program> for its long-term funding needs which enables UCB to issue unsecured bonds with a tenor of minimum 1 year within a € 5 billion program.

Debt financing

UCB has access to diversified funding sources. Per 31 December 2022, outstanding bonds included:

In addition to these bonds, UCB entered into a various loan agreements, including a bullet floating rate syndicated term loan maturing in 2025 in connection with the acquisition of Ra Pharmaceuticals, Inc, a bullet floating rate syndicated term loan maturing in 2027 in connection with the acquisition of Zogenix, Inc as well as various other bilateral loan agreements (including the Schuldscheindarlehen transactions entered into in November 2022).